Abstract
Summary and ConclusionsThe blood hydrolysate Sanguinin was tested in vivo in 268 albino mice accompanied by 221 untreated controls for its effectiveness against the beta-hemolytic Streptococcus zooepidemicus. Sanguinin solution (20 mg/ml) was inoculated subcutaneously (0.25 to 1.0 mg/mouse daily, usually for 4-6 days) either prior or after infection. Suppressive effect on the course of the infection was noted in all series of treated mice. A significant increase in survival time was noted in the pretreated series with an average survival percentage of 38.9 compared with 6.0 of the total of untreated controls. It does not appear that a direct correlation can be established between the survival rates and the intake of Sanguinin or the length of its administration, however, pretreatment seems to be of decisive value.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
